Adjuvant Chemoradiation Therapy for Pancreatic Adenocarcinoma: Who Really Benefits?

Nipun B. Merchant, Jennifer Rymer, Elizabeth A.S. Koehler, G. Daniel Ayers, Jason Castellanos, David A. Kooby, Sharon H. Weber, Clifford S. Cho, C. Max Schmidt, Atilla Nakeeb, Jesus M. Matos, Charles R. Scoggins, Robert C.G. Martin, Hong Jin Kim, Syed A. Ahmad, Carrie K. Chu, Rebecca McClaine, Brian K. Bednarski, Charles A. Staley, Kenneth SharpAlexander A. Parikh

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Background: The role of adjuvant chemoradiation therapy (CRT) in pancreatic cancer remains controversial. The primary aim of this study was to determine if CRT improved survival in patients with resected pancreatic cancer in a large, multiinstitutional cohort of patients. Study Design: Patients undergoing resection for pancreatic adenocarcinoma from seven academic medical institutions were included. Exclusion criteria included patients with T4 or M1 disease, R2 resection margin, preoperative therapy, chemotherapy alone, or if adjuvant therapy status was unknown. Results: There were 747 patients included in the initial evaluation. Primary analysis was performed between patients that had surgery alone (n = 374) and those receiving adjuvant CRT (n = 299). Median followup time was 12.2 months and 14.5 months for survivors. Median overall survival for patients receiving adjuvant CRT was significantly longer than for those undergoing operation alone (20.0 months versus 14.5 months, p = 0.001). On subset and multivariate analysis, adjuvant CRT demonstrated a significant survival advantage only among patients who had lymph node (LN)-positive disease (hazard ratio 0.477, 95% CI 0.357 to 0.638) and not for LN-negative patients (hazard ratio 0.810, 95% CI 0.556 to 1.181). Disease-free survival in patients with LN-negative disease who received adjuvant CRT was significantly worse than in patients who had surgery alone (14.5 months versus 18.6 months, p = 0.034). Conclusions: This large multiinstitutional study emphasizes the importance of analyzing subsets of patients with pancreas adenocarcinoma who have LN metastasis. Benefit of adjuvant CRT is seen only in patients with LN-positive disease, regardless of resection margin status. CRT in patients with LN-negative disease may contribute to reduced disease-free survival.

Original languageEnglish (US)
Pages (from-to)829-838
Number of pages10
JournalJournal of the American College of Surgeons
Issue number5
StatePublished - May 2009
Externally publishedYes

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Adjuvant Chemoradiation Therapy for Pancreatic Adenocarcinoma: Who Really Benefits?'. Together they form a unique fingerprint.

Cite this